Hello! Describe your research question and I'll help you find matching datasets across 2,944 studies from AnVIL, BDC, CRDC, and KFDRC.

Botensilimab, an Fc-enhanced Anti-CTLA-4 Antibody, is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy

No selected publications.